Trial reportNature2019
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
4 registry-linked trialsAbstract readClinical Trial
In one paragraph
Trial report in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 1,331 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,331citing papers in PubMed, 2 pooled it
183.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)
Safety and Efficacy of KRAS Vaccine in the Treatment of KRAS-mutant Malignancies
Who cites it
1,331 citing papers in PubMed, 2 syntheses or guidelines pooled it, 2,188 citations in OpenAlex.
- KRAS mutation and its association with clinicopathological features of colorectal cancer patients in Africa: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- KRAS G12C inhibitors in KRASFrontiers in immunology · 2026Pooled it
- KRAS-elicited PDIA6 blocks PERK-dependent immunogenic cell death in pancreatic carcinoma.Oncoimmunology · 2026Article
- Pan-Cancer Quantification of Driver Alteration Transmission Across Molecular Layers Reveals Limited Propagation to Protein Abundance.International journal of cancer · 2026Article
- Regression-Associated Macrophages Recruit Natural Killer Cells That Constrain Targeted Therapy Resistance.Cancer research · 2026Article
- Stereoretentive Nucleophilic Aromatic Substitution Accesses Atropisomeric 4-Amino-N-Arylquinolinium Salts.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nature genetics · 2026Article
- Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines.Translational lung cancer research · 2026Article
- Exploring the Neuroprotective Effects of Walnut (International journal of molecular sciences · 2026Article
- Review
- Engineered subtilisin protease degrades active KRAS in cancer cells leading to differential cell targeting.Research square · 2026Article
- Review
- The Landmark Series: Mutation-Based Therapy of Pancreatic Cancer.Annals of surgical oncology · 2026Review
- Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.Medical oncology (Northwood, London, England) · 2026Review
- Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.Medical oncology (Northwood, London, England) · 2026Review
- Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations.Journal of medicinal chemistry · 2026Article
- Changes in the transcriptome and synthetic lethal dependencies followingProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Chemical Genetic Targeting of the LRRK2 GTPase Domain.bioRxiv : the preprint server for biology · 2026Article
- Article
- Coordinated Immune Activation Following KRAS Inhibition in Syngeneic Models Reveals Molecular Pathways that Potentiate and Limit Antitumor Immunity.Cancer immunology research · 2026Article
1,271 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
34 authors at 9 institutions in 2 countries.
Jude CanonAmgen Research, Amgen Inc, Thousand Oaks, CA, USA. jcanon@amgen.com.
Karen Rex *Amgen Research, Amgen Inc, Thousand Oaks, CA, USA.
Anne Y Saiki *Amgen Research, Amgen Inc, Thousand Oaks, CA, USA.
Christopher MohrAmgen Research, Amgen Inc, Thousand Oaks, CA, USA.
Keegan CookeAmgen Research, Amgen Inc, Thousand Oaks, CA, USA.
Dhanashri BagalAmgen Research, Amgen Inc, South San Francisco, CA, USA.
Kevin GaidaAmgen Research, Amgen Inc, Thousand Oaks, CA, USA.
Tyler HoltAmgen Research, Amgen Inc, Thousand Oaks, CA, USA.
Charles G KnutsonAmgen Research, Amgen Inc, Cambridge, MA, USA.
Neelima KoppadaAmgen Research, Amgen Inc, Cambridge, MA, USA.
Brian A LanmanAmgen Research, Amgen Inc, Thousand Oaks, CA, USA.
Jonathan WernerAmgen Research, Amgen Inc, Thousand Oaks, CA, USA.
Aaron S RapaportAmgen Research, Amgen Inc, South San Francisco, CA, USA.
Tisha San MiguelAmgen Research, Amgen Inc, Thousand Oaks, CA, USA.
Roberto OrtizAmgen Research, Amgen Inc, Cambridge, MA, USA.
Tao OsgoodAmgen Research, Amgen Inc, Thousand Oaks, CA, USA.
Ji-Rong SunAmgen Research, Amgen Inc, Thousand Oaks, CA, USA.
Xiaochun ZhuAmgen Research, Amgen Inc, Cambridge, MA, USA.
John D McCarterAmgen Research, Amgen Inc, Thousand Oaks, CA, USA.
Laurie P VolakAmgen Research, Amgen Inc, Cambridge, MA, USA.
Brett E HoukAmgen Clinical Development, Amgen Inc, Thousand Oaks, CA, USA.
Marwan G FakihCity of Hope, Duarte, CA, USA.
Bert H O'NeilIndiana University School of Medicine, Indianapolis, IN, USA.
Timothy J PriceThe Queen Elizabeth Hospital, Woodville, South Australia, Australia.
Gerald S FalchookSarah Cannon Research Institute, Denver, CO, USA.
Jayesh DesaiPeter MacCallum Cancer Center, Melbourne, Victoria, Australia.
James KuoScientia Clinical Research, Randwick, New South Wales, Australia.
Ramaswamy GovindanWashington University School of Medicine, St Louis, MO, USA.
David S HongThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wenjun OuyangAmgen Research, Amgen Inc, South San Francisco, CA, USA.
Haby HenaryAmgen Clinical Development, Amgen Inc, Thousand Oaks, CA, USA.
Tara ArvedsonAmgen Research, Amgen Inc, South San Francisco, CA, USA.
Victor J CeeAmgen Research, Amgen Inc, Thousand Oaks, CA, USA.
J Russell LipfordAmgen Research, Amgen Inc, Thousand Oaks, CA, USA. jlipford@amgen.com.
Amgen (United States) · USCity of Hope · USIndiana University School of MedicinePeter MacCallum Cancer Centre · AUSarah Cannon · USTakeda (United States) · USThe University of Texas MD Anderson Cancer Center · USUniversity of Adelaide · AUWashington University in St. Louis · US
Funding
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI PAUL David ADAMS, Gregory L Hura · 2017 to 2026
$28.6MPilatus 6mS10OD021832 · OD · UNIVERSITY OF CALIFORNIA BERKELEY · PI ADAMS, PAUL DAVID · 2016 to 2016
$980kNIH HHS S10 OD021832
Abstract
KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumours
Indexed as
AnimalsAntineoplastic AgentsCell ProliferationDrug SynergismHumansImmunotherapyInflammationLung NeoplasmsMicePhosphorylationPiperazinesProto-Oncogene Proteins p21(ras)PyridinesPyrimidinesSignal TransductionTreatment OutcomeAntineoplastic AgentsKRAS protein, humanPiperazinesProto-Oncogene Proteins p21(ras)PyridinesPyrimidinessotorasib
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT03600883ClinicalTrials.gov
NCT04869475ClinicalTrials.gov
NCT05236114ClinicalTrials.gov
NCT07004244ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.